← Browse by Condition
Medical Condition
gastric or gastroesophageal junction adenocarcinoma
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 1, Phase 2, Phase 2
ClinicalMetric tracks all active clinical trials for gastric or gastroesophageal junction adenocarcinoma sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.
- Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
- Phase 1–4 studies from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary available for every trial listing
Trial Phases
Phase 1 1
Phase 2 2
Top Sponsors
1 trial
1 trial
NCT05482893 Phase 1, Phase 2
Recruiting
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Enrollment
258 pts
Location
United States
Sponsor
Phanes Therapeutics
NCT06587425 Phase 2
Recruiting
The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients With Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment
50 pts
Location
China
Sponsor
Shanghai Zhongshan Hospital